On Wednesday of this week, Israel’s Health Ministry announced that the Regeneron monoclonal antibody blend would henceforth be offered to COVID-19 patients considered at high risk of progressing to serious illness.
On Wednesday of this week, Israel’s Health Ministry announced that the Regeneron monoclonal antibody blend would henceforth be offered to COVID-19 patients considered at high risk of progressing to serious illness.